Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Titan Pharmaceuticals, Inc. (TTNP) had Return on Tangible Equity of -29.99% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-0.56M |
|
-- |
|
-- |
|
$0.53M |
|
$-0.53M |
|
$-0.03M |
|
$-0.56M |
|
$-0.56M |
|
$-0.56M |
|
$-0.56M |
|
$-0.56M |
|
$-0.56M |
|
$-0.53M |
|
$-0.53M |
|
0.91M |
|
0.91M |
|
$-0.62 |
|
$-0.62 |
|
| Balance Sheet Financials | |
$2.16M |
|
-- |
|
-- |
|
$2.16M |
|
$0.28M |
|
-- |
|
-- |
|
$0.28M |
|
$1.88M |
|
$1.88M |
|
$1.88M |
|
0.91M |
|
| Cash Flow Statement Financials | |
$-0.87M |
|
-- |
|
$-0.02M |
|
$2.83M |
|
$1.95M |
|
$-0.89M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.73 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.87M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-30.01% |
|
|
Return on Tangible Equity |
-29.99% |
-26.11% |
|
-29.99% |
|
$2.05 |
|
$-0.95 |
|
$-0.95 |
|